Cadisegliatin (TTP399)

October 6, 2026: vTv Therapeutics (NASDAQ: VTVT) announced a virtual KOL event for October 20, 2026 focused on cadisegliatin (TTP399), its investigational oral glucokinase activator for type 1 diabetes. The event will cover the T1D treatment landscape, hypoglycemia burden, and cadisegliatin’s development as an adjunctive therapy to insulin.

The company said cadisegliatin is being evaluated in the ongoing Phase 3 CATT1 trial in T1D, with topline data expected in mid-2027. The release describes cadisegliatin as a potential first-in-class, liver-selective oral therapy and notes it has received FDA Breakthrough Therapy designation.

No new clinical efficacy or safety data were reported in this announcement; the primary catalyst is the October 20, 2026 KOL event, with the next major development milestone being mid-2027 topline Phase 3 CATT1 data.